|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
US10202356B2
(en)
|
2013-03-14 |
2019-02-12 |
Tolero Pharmaceuticals, Inc. |
JAK2 and ALK2 inhibitors and methods for their use
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
BR112016028119A2
(pt)
|
2014-06-06 |
2017-08-22 |
Res Triangle Inst |
Agonistas receptores de apelina (apj) e usos dos mesmos
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
JP6708661B2
(ja)
|
2015-03-30 |
2020-06-10 |
ミッション セラピューティクス リミティド |
Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物
|
|
MX382355B
(es)
|
2015-04-10 |
2025-03-13 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
|
|
MX2017013275A
(es)
*
|
2015-04-15 |
2018-01-26 |
Araxes Pharma Llc |
Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
|
|
KR20180017013A
(ko)
*
|
2015-05-06 |
2018-02-20 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
K-Ras 조절제
|
|
WO2016200726A1
(en)
*
|
2015-06-08 |
2016-12-15 |
Texas Tech University System |
Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058807A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
AU2016366310C1
(en)
|
2015-12-09 |
2021-09-09 |
Research Triangle Institute |
Improved apelin receptor (APJ) agonists and uses thereof
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
ES2863873T3
(es)
|
2016-05-18 |
2021-10-11 |
Mirati Therapeutics Inc |
Inhibidores de KRAS G12C
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
EP3515889A1
(en)
|
2016-09-20 |
2019-07-31 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Trpv4 antagonists
|
|
TW201825458A
(zh)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產（第二）有限公司 |
Ｔｒｐｖ４拮抗劑
|
|
CA3036933A1
(en)
|
2016-09-20 |
2018-03-29 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Trpv4 antagonists
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
EP3555077B1
(en)
*
|
2016-12-15 |
2023-04-19 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
CN110366550A
(zh)
*
|
2016-12-22 |
2019-10-22 |
美国安进公司 |
作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
|
|
JP7219218B2
(ja)
|
2016-12-22 |
2023-02-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
|
|
WO2018143403A1
(ja)
|
2017-02-03 |
2018-08-09 |
国立大学法人東北大学 |
複素環化合物
|
|
ES2747768T3
(es)
|
2017-03-20 |
2020-03-11 |
Forma Therapeutics Inc |
Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
|
|
KR20200011426A
(ko)
|
2017-04-20 |
2020-02-03 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
K-ras 조절인자
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
IL274601B2
(en)
|
2017-11-15 |
2024-04-01 |
Mirati Therapeutics Inc |
Kras g12c inhibitors
|
|
TWI870922B
(zh)
|
2017-12-21 |
2025-01-21 |
德商百靈佳殷格翰國際股份有限公司 |
作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
|
|
CR20200464A
(es)
|
2018-03-08 |
2021-04-14 |
Incyte Corp |
Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
|
|
JP2021524835A
(ja)
|
2018-04-05 |
2021-09-16 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
Ａｘｌキナーゼ阻害剤およびその使用
|
|
WO2019204505A2
(en)
*
|
2018-04-18 |
2019-10-24 |
Theras, Inc. |
K-ras modulators with a vinyl sulfonamide moiety
|
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
US11090304B2
(en)
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
EP3807276B1
(en)
|
2018-06-12 |
2025-12-10 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
|
JP2021530554A
(ja)
|
2018-07-26 |
2021-11-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SG11202102377YA
(en)
|
2018-09-10 |
2021-04-29 |
Mirati Therapeutics Inc |
Combination therapies
|
|
EP3849536A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CA3111977A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020061255A1
(en)
|
2018-09-19 |
2020-03-26 |
Forma Therapeutics, Inc. |
Activating pyruvate kinase r
|
|
WO2020061378A1
(en)
|
2018-09-19 |
2020-03-26 |
Forma Therapeutics, Inc. |
Treating sickle cell disease with a pyruvate kinase r activating compound
|
|
EP3628664A1
(en)
|
2018-09-25 |
2020-04-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Irreversible inhibitors of kras g12c mutant
|
|
AU2019364417A1
(en)
*
|
2018-10-24 |
2021-05-20 |
Araxes Pharma Llc |
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis
|
|
TWI831855B
(zh)
*
|
2018-10-26 |
2024-02-11 |
日商大鵬藥品工業股份有限公司 |
新穎吲唑化合物或其鹽
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
*
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
AU2019384118B2
(en)
*
|
2018-11-19 |
2025-06-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
EP3890716A4
(en)
|
2018-12-05 |
2022-12-21 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
JP7592601B2
(ja)
|
2019-01-10 |
2024-12-02 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
CN109646680B
(zh)
*
|
2019-01-31 |
2020-02-11 |
四川大学华西医院 |
一种治疗kras突变型肠癌的联合用药物
|
|
CN113382774A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和krasg12c抑制剂的药物组合
|
|
US12281099B2
(en)
|
2019-02-26 |
2025-04-22 |
Boehringer Ingelheim International Gmbh |
Isoindolinone substituted indoles and derivatives as RAS inhibitors
|
|
CA3131156A1
(en)
|
2019-03-05 |
2020-09-10 |
Astrazeneca Ab |
Fused tricyclic compounds useful as anticancer agents
|
|
CN111662232B
(zh)
*
|
2019-03-06 |
2022-08-02 |
中国科学院上海药物研究所 |
具有2h-吲唑结构的小分子化合物及其合成和应用
|
|
US11198699B2
(en)
|
2019-04-02 |
2021-12-14 |
Aligos Therapeutics, Inc. |
Compounds targeting PRMT5
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
JP7092935B2
(ja)
|
2019-05-21 |
2022-06-28 |
アムジエン・インコーポレーテツド |
固体形態
|
|
WO2020239123A1
(zh)
*
|
2019-05-31 |
2020-12-03 |
上海翰森生物医药科技有限公司 |
芳香杂环类衍生物调节剂、其制备方法和应用
|
|
CN113993860B
(zh)
|
2019-06-25 |
2023-08-01 |
正大天晴药业集团股份有限公司 |
作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
|
|
PH12022550469A1
(en)
|
2019-08-29 |
2023-02-27 |
Array Biopharma Inc |
Kras g12d inhibitors
|
|
US20220378756A1
(en)
|
2019-09-19 |
2022-12-01 |
Forma Therapeutics, Inc. |
Activating pyruvate kinase r
|
|
EP4034123A4
(en)
|
2019-09-24 |
2023-11-01 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
CN112225734B
(zh)
*
|
2019-10-25 |
2021-12-07 |
南京瑞捷医药科技有限公司 |
Kras g12c抑制剂及其用途
|
|
CA3158793A1
(en)
|
2019-10-28 |
2021-05-06 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
CN115551500A
(zh)
|
2019-10-31 |
2022-12-30 |
大鹏药品工业株式会社 |
4-氨基丁-2-烯酰胺衍生物及其盐
|
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
US11608346B2
(en)
|
2019-11-04 |
2023-03-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
IL320513A
(en)
|
2019-11-04 |
2025-06-01 |
Revolution Medicines Inc |
RAS inhibitors
|
|
CN110698378B
(zh)
*
|
2019-11-19 |
2021-03-19 |
上海皓元生物医药科技有限公司 |
2-(羟基-(甲基环丙基)苯基氨基)-1-哌嗪基乙酮衍生物的制备方法
|
|
BR112022009881A2
(pt)
*
|
2019-11-22 |
2022-10-11 |
Univ California |
Inibidores de caspase 6 e usos dos mesmos
|
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
WO2021106230A1
(ja)
|
2019-11-29 |
2021-06-03 |
大鵬薬品工業株式会社 |
新規なフェノール化合物又はその塩
|
|
KR20220130126A
(ko)
|
2019-12-20 |
2022-09-26 |
미라티 테라퓨틱스, 인크. |
Sos1 억제제
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
US20230181536A1
(en)
*
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
|
EP4139299B1
(en)
*
|
2020-04-24 |
2025-12-17 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
WO2021219090A1
(zh)
*
|
2020-04-29 |
2021-11-04 |
北京泰德制药股份有限公司 |
喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
|
TW202210633A
(zh)
|
2020-06-05 |
2022-03-16 |
法商昂席歐公司 |
用於治療癌症之dbait分子與kras抑制劑的組合
|
|
EP4168002A1
(en)
|
2020-06-18 |
2023-04-26 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
KR20230137286A
(ko)
|
2020-09-11 |
2023-10-04 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제의 결정 형태
|
|
US11690915B2
(en)
|
2020-09-15 |
2023-07-04 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN114249703B
(zh)
*
|
2020-09-25 |
2023-10-13 |
四川科瑞德制药股份有限公司 |
适合工业放大的医药中间体的制备方法
|
|
MX2023007084A
(es)
|
2020-12-15 |
2023-08-30 |
Mirati Therapeutics Inc |
Inhibidores de pan-kras de azaquinazolina.
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022140246A1
(en)
|
2020-12-21 |
2022-06-30 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
US20240051956A1
(en)
|
2020-12-22 |
2024-02-15 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|
|
WO2022232320A1
(en)
|
2021-04-27 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
CN118561952A
(zh)
|
2021-05-05 |
2024-08-30 |
锐新医药公司 |
Ras抑制剂
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
KR20240024928A
(ko)
|
2021-06-23 |
2024-02-26 |
노파르티스 아게 |
Kras 돌연변이 단백질의 억제제로서의 피라졸릴 유도체
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
AU2022315228A1
(en)
|
2021-07-23 |
2024-02-08 |
Lawrence Livermore National Security, Llc |
Compositions and methods for inhibition of ras
|
|
IL309086A
(en)
|
2021-09-01 |
2024-02-01 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
TW202322819A
(zh)
|
2021-10-22 |
2023-06-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
含氮的四環化合物、其製備方法及其在醫藥上的應用
|
|
CN113956233B
(zh)
*
|
2021-10-22 |
2023-06-06 |
南方医科大学 |
一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
|
|
CN114380682A
(zh)
*
|
2021-10-27 |
2022-04-22 |
上海毕得医药科技股份有限公司 |
一种2,3-二氟-4-甲氧基苯乙酸合成方法
|
|
US20250282782A1
(en)
|
2021-12-17 |
2025-09-11 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
US20250154170A1
(en)
|
2022-02-10 |
2025-05-15 |
Bayer Aktiengesellschaft |
Fused pyrimidines as kras inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2023377064A1
(en)
|
2022-11-09 |
2025-05-22 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|
|
WO2024182447A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Vividion Therapeutics, Inc. |
Compounds and methods for modulating ras-pi3k
|
|
WO2024201691A1
(ja)
|
2023-03-28 |
2024-10-03 |
国立大学法人東北大学 |
オートファジーを誘導する化合物のスクリーニング方法
|
|
CR20250458A
(es)
|
2023-03-30 |
2025-11-21 |
Revolution Medicines Inc |
Composiciones para inducir la hidrólisis de ras gtp y sus usos
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
CN121219016A
(zh)
|
2023-06-02 |
2025-12-26 |
第一三共株式会社 |
抗-her3抗体-药物缀合物和rasg12c抑制剂的组合
|
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
GB2633813A
(en)
|
2023-09-21 |
2025-03-26 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US12466840B2
(en)
|
2023-10-20 |
2025-11-11 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of KRAS proteins
|
|
WO2025083426A1
(en)
|
2023-10-20 |
2025-04-24 |
Sevenless Therapeutics Limited |
New treatments for pain
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025146548A1
(en)
|
2024-01-04 |
2025-07-10 |
Sevenless Therapeutics Limited |
Sos1 inhibitors useful to treat pain and cancer
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
CN119039303A
(zh)
*
|
2024-09-20 |
2024-11-29 |
上海信诺维生物医药有限公司 |
一种螺环化合物
|